Impact of Combination Therapies and CNS Efficacy in EGFR-Mutant NSCLC Treatment
Experts consider the influence of combination therapies on EGFR-mutant lung cancer treatment, including the impact on central nervous system (CNS) response, challenges in CNS metastases management, and the potential alternatives to whole-brain radiation.
Video Player is loading.
EP: 1.Biomarker Testing and Advancements in EGFR-Mutant NSCLC Treatment Strategies
EP: 2.Revolutionizing First-Line Strategies in EGFR-Mutant NSCLC: Combination Therapies
Now Viewing
EP: 3.Impact of Combination Therapies and CNS Efficacy in EGFR-Mutant NSCLC Treatment
EP: 4.EGFR-Mutant NSCLC: Second-Line Treatment Options and Safety Data
EP: 5.Advancements in EGFR-Mutant NSCLC: ADCs and Other Targeted Therapies
EP: 6.EGFR Exon 20 Insertion NSCLC: A Comprehensive Overview
EP: 7.Unmet Needs in EGFR Exon 20 Insertion Non–Small Cell Lung Cancer
EP: 8.“Exciting Year” for Targeted Therapy Options for Mutated NSCLC, Experts Say
Recent Videos
Managing Epithelioid Sarcoma: Follow-Up Strategies and Treatment Decisions for Stable Disease vs Progression
Navigating Frontline Therapy in Epithelioid Sarcoma: Key Clinical Considerations and Shared Decision-Making
Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation
Institutional Implementation: Setting Up Tarlatamab Administration
Divarasib Combo Appears “Promising” in Pretreated KRAS G12C+ NSCLC
Choosing Between Tazemetostat and Zanubrutinib+Obinutuzumab: Key Factors & Patient Conversations
Expert Perspectives: Tazemetostat in R/R FL
Management Strategies for Localized Epithelioid Sarcoma: The Role of Neoadjuvant and Adjuvant Therapies
Key Takeaways and Future Perspectives: PSMA PET Imaging in Prostate Cancer
Evaluating the Role of Cu-PSMA PET Imaging in Prostate Cancer
Related Content
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
